no lives were destroyed simply because there never was a 1 mg halcion tablet.
and regarding withdrawals, Dr. Ashton claimed that triazolam withdrawals were nowhere as vicious as lorazepam, alprazolam, or temazepam wds because of the fact that its half life was too short.
Dr. Ashton's own words
You are wrong, wrong, wrong. Although my memory is hazy at best, Upjohn was approved for marketing in the Netherlands in 1977 at 0.25, 0.5 and 1.0 mg strengths.
Although what I was prescribed in the U.S. in 1989 were the .5's I also was buying them offshore from another source years before that.
I suggest you do your homework before sounding like a dimestore quack.
Here is my source:
http://www.sussex.ac.uk/sociology/documents/ssm02.pdf
Now where is your source?
-owned
Appendix A. Chronology of Halcion events
1977 Approved for marketing in the Netherlands
at 0.25, 0.5 and 1.0 mg strengths
1978 Upjohn cite P321 data as reassurance of
long-term safety to UK CSM
1978 Approved for marketing in the UK at 0.125
and 0.25mg strengths
1979 Van der Kroefand hundreds ofother
Dutch doctors report adverse psychiatric
effects
1979 Banned in the Netherlands
1979 Boston ‘thought leader conference’ chaired
by Ayd
1979 Lancet letter casting doubt on validity of
van der Kroef’s reports
1979/1980 Upjohn undertake ‘comprehensive review
ofall available evidence’ pertaining to
safety concerns in the Netherlands
1982 UK CSM states that the adverse experiences
seem unique to the Netherlands,
where the dose used was at least double
that recommended in the UK
1982 Approved for marketing in the US at 0.125,
0.25 and 0.5 mg strengths
1982 Oswald clinical trials suggest less safe than
other hypnotics
1982 US FDA inform Upjohn that a principal
clinical investigator on pre-marketing Halcion
clinical trials is disqualified for submitting
false data
1984 US FDA inform Upjohn that a clinical
investigator on pre-marketing Halcion clinical
trials is disqualified for submitting false
data
1985 Dutch Council ofState (Crown Court)
reverses the Dutch regulatory authority’s
banning
1986 Halcion receives far more spontaneous
adverse drug reaction reports than any
other benzodiazepines in the UK since its
marketing
1987 Recommended dosage change in US from
0.5 to 0.25 mg
1989 Oswald calls for withdrawal from market
on safety grounds
1990 Dutch regulatory authorities required to
‘reapprove’ at 0.125 and 0.25 mg strengths
1990/1991 Grundberg litigation in US discovers
wholesale omissions ofmedical events in
reporting ofP321
1991 UK MCA learn that P321 data submitted
initially were unreliable and that the protocol
implies significant association with
adverse psychiatric effects, seemingly confirming
van der Kroef
1991 UK MCA learn that some key clinical
investigators have been disqualified by the
FDA because ofsubmission off alse data
1991 Licence suspended in UK on advice of
CSM
1992 UK Medicines Commission recommends
return to market at 0.125 mg strength only
1993 UK Panel of‘Appointed Persons’ recommends
return to market at strengths 0.0625,
0.125 and 0.25mg
1993 Banned in UK, accepting the view ofthe
CSM above others